Literature DB >> 28667390

Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.

Claudia Kessler1,2, Alessa Pardo2, Mehmet K Tur3, Stefan Gattenlöhner3, Rainer Fischer1,4, Katharina Kolberg1,2, Stefan Barth5.   

Abstract

PURPOSE: Despite great progress in the diagnosis and treatment of localized prostate cancer (PCa), there remains a need for new diagnostic markers that can accurately distinguish indolent and aggressive variants. One promising approach is the antibody-based targeting of prostate stem cell antigen (PSCA), which is frequently overexpressed in PCa. Here, we show the construction of a molecular imaging probe comprising a humanized scFv fragment recognizing PSCA genetically fused to an engineered version of the human DNA repair enzyme O6-alkylguanine-DNA alkyltransferase (AGT), the SNAP-tag, enabling specific covalent coupling to various fluorophores for diagnosis of PCa. Furthermore, the recombinant immunotoxin (IT) PSCA(scFv)-ETA' comprising the PSCA(scFv) and a truncated version of Pseudomonas exotoxin A (PE, ETA') was generated.
METHODS: We analyzed the specific binding and internalization behavior of the molecular imaging probe PSCA(scFv)-SNAP in vitro by flow cytometry and live cell imaging, compared to the corresponding IT PSCA(scFv)-ETA'. The cytotoxic activity of PSCA(scFv)-ETA' was tested using cell viability assays. Specific binding was confirmed on formalin-fixed paraffin-embedded tissue specimen of early and advanced PCa.
RESULTS: Alexa Fluor® 647 labeling of PSCA(scFv)-SNAP confirmed selective binding to PSCA, leading to rapid internalization into the target cells. The recombinant IT PSCA(scFv)-ETA' showed selective binding leading to internalization and efficient elimination of target cells.
CONCLUSIONS: Our data demonstrate, for the first time, the specific binding, internalization, and cytotoxicity of a scFv-based fusion protein targeting PSCA. Immunohistochemical staining confirmed the specific ex vivo binding to primary PCa material.

Entities:  

Keywords:  Immunotoxin (IT); Prostate cancer; Prostate stem cell antigen (PSCA); Pseudomonas exotoxin A (ETA′); SNAP-tag; Single-chain fragment variable (scFv)

Mesh:

Substances:

Year:  2017        PMID: 28667390     DOI: 10.1007/s00432-017-2472-9

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.322


  94 in total

1.  Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice.

Authors:  S Barth; M Huhn; B Matthey; R Schnell; S Tawadros; T Schinköthe; J Lorenzen; V Diehl; A Engert
Journal:  Int J Cancer       Date:  2000-06-01       Impact factor: 7.396

2.  Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-alkylguanine DNA alkyltransferase.

Authors:  Florian Kampmeier; Markus Ribbert; Thomas Nachreiner; Sofia Dembski; Florent Beaufils; Andreas Brecht; Stefan Barth
Journal:  Bioconjug Chem       Date:  2009-05-20       Impact factor: 4.774

3.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

Authors:  T Yokota; D E Milenic; M Whitlow; J Schlom
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

4.  Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein.

Authors:  Florian Kampmeier; Judith Niesen; Alexander Koers; Markus Ribbert; Andreas Brecht; Rainer Fischer; Fabian Kiessling; Stefan Barth; Theo Thepen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-07       Impact factor: 9.236

5.  A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.

Authors:  Ursula Elsässer-Beile; Philipp Wolf; Dorothee Gierschner; Patrick Bühler; Wolfgang Schultze-Seemann; Ulrich Wetterauer
Journal:  Prostate       Date:  2006-09-15       Impact factor: 4.104

Review 6.  Immunotoxin treatment of cancer.

Authors:  Ira Pastan; Raffit Hassan; David J FitzGerald; Robert J Kreitman
Journal:  Annu Rev Med       Date:  2007       Impact factor: 13.739

7.  Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).

Authors:  Richard Cathomas; Christian Rothermundt; Dirk Klingbiel; Lukas Bubendorf; Rolf Jaggi; Daniel C Betticher; Peter Brauchli; Denise Cotting; Cornelia Droege; Ralph Winterhalder; Daniele Siciliano; Dominik R Berthold; Miklos Pless; Ralph Schiess; Roger von Moos; Silke Gillessen
Journal:  Clin Cancer Res       Date:  2012-09-12       Impact factor: 12.531

8.  Prostate stem cell antigen antibody-conjugated multiwalled carbon nanotubes for targeted ultrasound imaging and drug delivery.

Authors:  Huixia Wu; Haili Shi; Hao Zhang; Xue Wang; Yan Yang; Chao Yu; Caiqin Hao; Jing Du; He Hu; Shiping Yang
Journal:  Biomaterials       Date:  2014-04-05       Impact factor: 12.479

9.  Sipuleucel-T for the Treatment of Patients With Metastatic Castrate-resistant Prostate Cancer: Considerations for Clinical Practice.

Authors:  Christopher M Pieczonka; Dimitrios Telonis; Vladimir Mouraviev; David Albala
Journal:  Rev Urol       Date:  2015

10.  Characterization of a novel single-chain bispecific antibody for retargeting of T cells to tumor cells via the TCR co-receptor CD8.

Authors:  Irene Michalk; Anja Feldmann; Stefanie Koristka; Claudia Arndt; Marc Cartellieri; Armin Ehninger; Gerhard Ehninger; Michael P Bachmann
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

View more
  4 in total

1.  EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment.

Authors:  Chaoyu Zhang; Wenjie Sheng; Marwah Al-Rawe; T M Mohiuddin; Marcus Niebert; Felix Zeppernick; Ivo Meihold-Heerlein; Ahmad Fawzi Hussain
Journal:  Int J Mol Sci       Date:  2022-05-30       Impact factor: 6.208

Review 2.  Human Granzyme B Based Targeted Cytolytic Fusion Proteins.

Authors:  Precious Hlongwane; Neelakshi Mungra; Suresh Madheswaran; Olusiji A Akinrinmade; Shivan Chetty; Stefan Barth
Journal:  Biomedicines       Date:  2018-06-20

3.  Immunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens.

Authors:  Devivasha Bordoloi; Peng Xiao; Hyeree Choi; Michelle Ho; Alfredo Perales-Puchalt; Makan Khoshnejad; J Joseph Kim; Laurent Humeau; Alagarsamy Srinivasan; David B Weiner; Kar Muthumani
Journal:  Genes Cancer       Date:  2021-03-22

Review 4.  Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy.

Authors:  Paola Muñoz-López; Rosa María Ribas-Aparicio; Elayne Irene Becerra-Báez; Karla Fraga-Pérez; Luis Fernando Flores-Martínez; Armando Alfredo Mateos-Chávez; Rosendo Luria-Pérez
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.